Kodiak Sciences Executive Compensation (FY25)
KOD · Executive and director compensation, fiscal 2025 only
The Kodiak Sciences brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Data as of September 7, 2026Latest filing (8-K): June 4, 2026
6 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
79 figures on this page: 74 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.
Frequently asked questions
Answers drawn from the data on this page.
Who is Kodiak Sciences' chief executive and what were they paid?
Victor Perlroth was paid $2,499,221 in total compensation as Chief Executive Officer and Chairman of the Board for fiscal 2025.
What was Kodiak Sciences' say-on-pay result?
Shareholders recorded 99.3% support for the say-on-pay proposal at the meeting held June 2, 2026 for fiscal 2025.
Which companies are in Kodiak Sciences' peer group?
The disclosed peer group includes 4D Molecular Therapeutics, AbCellera Biologics, Allogene Therapeutics, EyePoint Pharmaceuticals and Fate Therapeutics, among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Victor Perlroth Chief Executive Officer and Chairman of the Board | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
John Borgeson Executive Vice President, Chief Financial Officer and Secretary | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| John Borgeson | OPTION | — | — | — | — | — | — | ◇ |
| Victor Perlroth | OPTION | — | — | — | — | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| John Borgeson | Option | ◇ | — | ◇ | 6/23/2033 |
| Option | ◇ | — | ◇ | 8/4/2034 | |
| Option | ◇ | — | ◇ | 7/5/2032 | |
| Victor Perlroth | Option | ◇ | — | ◇ | 7/5/2032 |
| Option | ◇ | — | ◇ | 8/4/2034 | |
| Option | ◇ | — | ◇ | 7/3/2035 | |
| Option | ◇ | — | ◇ | 6/23/2033 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
John Borgeson
Executive Vice President, Chief Financial Officer and Secretary · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance multiple | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
| Excise tax treatment | ◇ |
Victor Perlroth
Chief Executive Officer and Chairman of the Board · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
| Excise tax treatment | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Robert A. Profusek, J.D Lead independent director | ◇ | — | ◇ | — | — | — | ◇ |
Charles A. Bancroft | ◇ | — | ◇ | — | — | — | ◇ |
Bassil I. Dahiyat, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Taiyin Yang, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Richard S. Levy, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Felix J. Baker, Ph.D | — | — | ◇ | — | — | — | ◇ |
Victor Perlroth, M.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Lead independent director premium | ◇ |
| Audit committee member | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- 4D Molecular Therapeutics FDMT
- AbCellera Biologics ABCL
- Allogene Therapeutics ALLO
- EyePoint Pharmaceuticals EYPT
- Fate Therapeutics FATE
- Heron Therapeutics HRTX
- Mersana Therapeutics MRSN
- Nektar Therapeutics NKTR
- RAPT Therapeutics RAPT
- Viridian Therapeutics VRDN
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 2, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 2, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 4, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | June 6, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 7, 2022 | = | ◇ | ◇ | ◇ |
What this page does not include
Everything above is a fact Kodiak Sciences disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Kodiak Sciences sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
79 figures on this page: 74 cited to the filing that reported them, 5 calculated from figures it prints.
74 cited to the filing
5 calculated from the filing
Documents cited
- 0001193125-26-257766Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-26-1704292025 Outstanding Equity Awards at Fiscal Year-End Table · 2025 Summary Compensation Table · Compensation Discussion and Analysis · Non-Employee Director Compensation · and 2 more sections
- 0001193125-25-134149Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-24-156056Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-23-162502Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-22-169440Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Kodiak Sciences executive compensation, FY2025.” https://intel.velarion.ai/comp/KOD (accessed 2026).
Short form: data: Velarion
The Kodiak Sciences brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
6 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Kodiak Sciences and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Kodiak Sciences discloses
The companies named in KOD's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}